Safety and Efficacy of Glucagon-like peptide 1 agonists in dialysis patients

Not Applicable

• Conditions: End stage kidney disease; Diabetes; Renal and Urogenital - Kidney disease; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12623000862640
• Lead Sponsor: Auckland City Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-08-11
• Last Update Posted: 21 August 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 95

Inclusion Criteria

1.Type 2 diabetes.
2.Stable on either haemodialysis, peritoneal dialysis or hybrid therapy (both haemodialysis and peritoneal dialysis) for at least 3 months.
3.Aged 18 years old or older
4.Able to give informed consent.
5.HbA1c >53mmol/mol

Exclusion Criteria

Exclusion criteria
1.Known allergy or adverse drug effect to GLP-1 receptor agonists
2.Known severe hepatic dysfunction such as portal hypertension or cirrhosis, acute or chronic hepatitis, signs or symptoms of other liver disease, or an alanine transaminase (ALT) level >3 times the upper limit of normal
3.Have a past history of acute, chronic or idiopathic pancreatitis
4.Excessive alcohol intake above recommended levels
5.Type 1 diabetes
6.Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B
7.Malnutrition
8.Pregnancy
9.Planning for coronary, carotid or peripheral artery revascularisation
10.Known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction) or had undergone gastric bypass (bariatric) surgery
11.Acute coronary syndrome or cerebrovascular event within 14 days prior to screening
12.In the judgement of the investigator, have any other condition that is likely to limit protocol compliance or reporting of adverse events

Study & Design

• Study Type: Interventional
• Study Design: Not specified